D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target

Benzinga · 10/27 12:39
D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $25 price target.